4DMedical (FRA:MQ7) Beta: N/A (As of Jul. 11, 2026)


FRA:MQ7 4DMedical Ltd FRA:MQ7
37 GF Score
Price €2.30
GF Value €0.83
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-11), 4DMedical's Beta is Not available.

4DMedical  (FRA:MQ7) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

4DMedical Beta Related Terms

4DMedical Beta Historical Data

* Premium members only.

The historical data trend for 4DMedical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical Beta Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:MQ7
37GF Score
4DMedical Ltd FRA:MQ7
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is 4DMedical (FRA:MQ7) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of €2.30 is trading 177.1% above its estimated GF Value™ of €0.83. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for FRA:MQ7:

  • Beta: N/A
  • GF Value™: €0.83 vs. price of €2.30 (177.1% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the FRA:MQ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USA4DX:Australia
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
37GF Score

Get the complete analysis for FRA:MQ7

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.30
Price
€0.83
GF Value